Skip to content
Sign in
StableHealthReported 2026-11-20 13:14

Caliway's CBL-514 Receives Early IND Clearance in China

Caliway Biopharmaceuticals' China clinical trial (CBL-0102) for the injectable drug candidate CBL-514 received early authorization to proceed from China's NMPA ahead of schedule, with subject enrollment expected to begin in December 2026 and clinical data anticipated in Q2 2027.

Why it matters. The early IND clearance accelerates Caliway's development timeline in China, the world's fastest-growing body contouring market projected to reach RMB 643 billion by 2040, and supports potential regulatory submissions across other Asian…

01

Who and what it touches

CBL-514part ofNew Taipei Citylocated inCaliway Biophar…

Into Caliway Biopharmaceuticals

From Caliway Biopharmaceuticals

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-20 13:14
    The trial is expected to begin subject enrollment in December 2026
    View source